At the 2012 Transcatheter Cardiovascular Therapeutics (TCT; 22–26 October, Miami, USA) meeting, reporting on the results of an economic analysis of the FAME II study, William Fearon, Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, USA, said that fractional flow reserve (FFR) guided percutaneous coronary intervention (PCI) was cost-effective, compared with medical management, in patients with stable coronary disease (CAD).
InspireMD has announced that the randomised 432-patient MASTER trial of its embolic protective MGuard Embolic Protection Coronary Stent (EPS) has been published in the 6 November print edition of the Journal of American College of Cardiology.
The results from a five-year study of diabetics with diseased arteries has found that patients who have bypass surgery fare significantly better than those who undergo clearing procedures supported by implanted drug-coated stents.
(Reuters) - St Jude Medical Inc said on Monday its procedure that deadens nerves near the kidneys helped lower blood pressure in a small study of patients whose hypertension could not be controlled with drugs.
People with diabetes mellitus who undergo heart bypass surgery for multiple blocked arteries have a significantly better five-year survival rate than diabetic patients who undergo angioplasty with drug-eluting stents (DES), according to a study published in the November 2012 issue of The Annals of Thoracic Surgery.
The results from a five-year study of diabetics with diseased arteries has found that patients who have bypass surgery fare significantly better than those who undergo clearing procedures supported by implanted drug-coated stents.
Boston Scientific has received CE mark approval for the Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.
SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Fish & Richardson scored a major victory for San Diego based Volcano Corporation in a patent trial regarding medical device technology used to diagnose heart problems. After less than 90 minutes of deliberation, a federal district court jury in Delaware found that Volcano did not infringe two patents asserted by St. Jude Medical Inc. and that another two St. Jude patents were invalid. A fifth St. Jude patent was declared not infringed by the court on the eve of trial. The lawsuit, filed in 2010 by St. Jude, sought to shut down Volcano s rapidly growing cardiac Functional Management business. The verdict was delivered on October 19, 2012 and was initially subject to an agreement by the parties not to issue press releases.
WAYNE, N.J., Oct. 29, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE mark approval for its new SENSATION PLUS® 7.5Fr. 40cc intra-aortic balloon (IAB) catheter.
Results of the XIMA trial presented at TCT 2012
España, octubre de 2012.- Daiichi Sankyo Company, Limited ha anunciado que ha completado el reclutamiento de pacientes para el estudio global de fase 3, Hokusai-VTE. La investigación analiza el papel del inhibidor oral del factor Xa de toma única diaria edoxabán en el tratamiento y prevención de la recurrencia de tromboembolismo venoso (TEV), en pacientes que han padecido una trombosis venosa profunda (TVP) sintomática y aguda, embolia pulmonar (EP) o ambos.1,2
Twelve-month results from the DELUX registry demonstrating excellent safety and efficacy for the Pantera Lux Paclitaxel Releasing Balloon in 1,064 patients were presented by Gert Richardt, Segeberger Heart Center Clinic, Germany, and Christoph K Naber, Elisabeth Hospital, Germany, at the Transcatheter Cardiovascular Therapeutics congress in Miami, USA.
On 29 October 2012, Maquet Cardiovascular announced that it has received 510(k) clearance from the FDA and CE mark approval for its new Sensation Plus 7.5F 40cc intra-aortic balloon catheter. This new larger-volume, fibre-optic intra-aortic balloon catheter will allow clinicians to provide a higher-efficacy, faster intra-aortic balloon counterpulsation therapy to smaller patients – those who are 5’0” to 5’4” tall (152–162cm). It will be available for sale in the United States and in the European Union in October.
St Jude Medical has announced results from its RESPECT trial, which studied the Amplatzer PFO Occluder in the prevention of recurrent cryptogenic stroke. Evidence presented at a late breaking trial session during the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, shows that the primary analysis was not statistically significant but trended towards superiority, while additional analyses demonstrated superiority. Stroke risk reduction was observed across the totality of analyses with rates ranging from 46.6– 72.7%.
Results from the EXCELLA II randomised trial presented at TCT 2012 have shown lower re-intervention rates with the DESyne Novolimus Eluting Coronary Stent System compared with the Endeavor zotarolimus-eluting system.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos